HK1055963A1 - Valsartan salts - Google Patents

Valsartan salts

Info

Publication number: HK1055963A1
Authority: HK; Hong Kong
Prior art keywords: valsartan; salts; valsartan salts
Prior art date: 2000-07-19

Application number

HK03108267.6A

Other languages

English (en)

Inventor

Erwin Marti

Hans Rudolf Oswald

Peter Buehlmayer

Wolfgang Marterer

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-19

Filing date

2003-11-13

Publication date

2004-01-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8169294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1055963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-11-13 Application filed by Novartis Ag filed Critical Novartis Ag

2004-01-30 Publication of HK1055963A1 publication Critical patent/HK1055963A1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Epidemiology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

HK03108267.6A 2000-07-19 2003-11-13 Valsartan salts HK1055963A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00115556		2000-07-19
PCT/EP2001/008253 WO2002006253A1 (en)	2000-07-19	2001-07-17	Valsartan salts

Publications (1)

Publication Number	Publication Date
HK1055963A1 true HK1055963A1 (en)	2004-01-30

Family

ID=8169294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK03108267.6A HK1055963A1 (en)	2000-07-19	2003-11-13	Valsartan salts

Country Status (31)

Country	Link
US (5)	US20030207930A1 (pt)
EP (1)	EP1313714B1 (pt)
JP (1)	JP4102664B2 (pt)
KR (1)	KR100529658B1 (pt)
CN (2)	CN1216873C (pt)
AR (2)	AR032758A1 (pt)
AT (1)	ATE406355T1 (pt)
AU (2)	AU2001289672B2 (pt)
BR (1)	BR0112665A (pt)
CA (1)	CA2415962C (pt)
CY (1)	CY1108559T1 (pt)
CZ (1)	CZ303389B6 (pt)
DE (1)	DE60135560D1 (pt)
DK (1)	DK1313714T3 (pt)
EC (1)	ECSP034436A (pt)
ES (1)	ES2309090T3 (pt)
HK (1)	HK1055963A1 (pt)
HU (1)	HU229280B1 (pt)
IL (2)	IL153882A0 (pt)
MX (1)	MXPA03000525A (pt)
MY (2)	MY136446A (pt)
NO (1)	NO326504B1 (pt)
NZ (1)	NZ523557A (pt)
PE (1)	PE20020613A1 (pt)
PL (1)	PL205715B1 (pt)
PT (1)	PT1313714E (pt)
RU (1)	RU2275363C2 (pt)
SI (1)	SI1313714T1 (pt)
SK (1)	SK287558B6 (pt)
WO (1)	WO2002006253A1 (pt)
ZA (1)	ZA200300285B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100529658B1 (ko)	2000-07-19	2005-11-21	노파르티스 아게	발사르탄 염
KR100984939B1 (ko) *	2002-01-17	2010-10-01	노파르티스 아게	발사르탄 및 ｎｅｐ 저해제를 포함하는 제약학적 조성물
US7468390B2 (en)	2002-01-17	2008-12-23	Novartis Ag	Methods of treatment and pharmaceutical composition
US6869970B2 (en) *	2002-02-04	2005-03-22	Novartis Ag	Crystalline salt forms of valsartan
AU2003223637A1 (en) *	2002-04-15	2003-11-03	Dr. Reddy's Laboratories Limited	Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- (2'-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl) amine (valsartan)
CN1662256A (zh) *	2002-05-17	2005-08-31	诺瓦提斯公司	用于心肌梗死二级预防的血管紧张素Ⅱ受体阻断剂和β－阻断剂的组合
EG24716A (en)	2002-05-17	2010-06-07	Novartis Ag	Combination of organic compounds
JP2005532362A (ja) *	2002-06-13	2005-10-27	ノバルティスアクチエンゲゼルシャフト	インドール誘導スタチンのカルシウム塩
GB0222056D0 (en) *	2002-09-23	2002-10-30	Novartis Ag	Process for the manufacture of organic compounds
WO2004083192A1 (en) *	2003-03-17	2004-09-30	Teva Pharmaceutical Industries Ltd.	Polymorphis of valsartan
EP1950204A1 (en)	2003-03-17	2008-07-30	Teva Pharmaceutical Industries Ltd.	Amorphous form of valsartan
US7199144B2 (en)	2003-04-21	2007-04-03	Teva Pharmaceuticals Industries, Ltd.	Process for the preparation of valsartan and intermediates thereof
AU2003223106A1 (en) *	2003-03-31	2004-10-25	Hetero Drugs Limited	A novel amorphous form of valsartan
TW200505879A (en) *	2003-04-21	2005-02-16	Teva Pharma	Process for the preparation of valsartan
WO2005049587A1 (en) *	2003-11-21	2005-06-02	Ranbaxy Laboratories Limited	Process for preparation of biphenyl tetrazole
WO2006002983A1 (en) *	2004-07-06	2006-01-12	Novartis Ag	Combination of organic compounds
EP1674080A1 (en) *	2004-12-24	2006-06-28	KRKA, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
WO2006066961A1 (en) *	2004-12-24	2006-06-29	Krka, D.D., Novo Mesto	Solid pharmaceutical composition comprising valsartan
GB0503062D0 (en) *	2005-02-14	2005-03-23	Novartis Ag	Combination of organic compounds
WO2007017897A2 (en) *	2005-05-25	2007-02-15	Ipca Laboratories Ltd.	Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
FR2886642B1 (fr) *	2005-06-06	2008-05-30	Sanofi Aventis Sa	Sels alcalino-terreux d'irbesartan et leur preparation
WO2007045663A2 (en) *	2005-10-19	2007-04-26	Novartis Ag	Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
RU2459809C2 (ru) *	2005-11-09	2012-08-27	Новартис Аг	Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
WO2007071750A1 (en) *	2005-12-22	2007-06-28	Enantia, S.L.	Intermediates and processes for the preparation of valsartan
WO2008035364A2 (en) *	2006-06-23	2008-03-27	Usv Limited	Process for the preparation of micronized valsartan
WO2008018843A1 (en) *	2006-08-08	2008-02-14	Ulkar Kimya Sanayi Ve Ticaret As	Process for producing useful salts form of biphenyl-tetrazole compounds
US20080152717A1 (en) *	2006-12-14	2008-06-26	Isp Investments, Inc.	Amorphous valsartan and the production thereof
JP2010526126A (ja) *	2007-05-07	2010-07-29	シプラ・リミテッド	バルサルタンの製造方法
ATE412640T1 (de) *	2007-06-07	2008-11-15	Inke Sa	Verfahren zur gewinnung eines zur gewinnung von valsartan nützlichen valsartan-salzes
CN104119336B (zh) *	2007-10-05	2016-08-24	维拉斯通股份有限公司	嘧啶取代的嘌呤衍生物
DK2295035T3 (en)	2007-11-06	2016-08-29	Novartis Ag	Double acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonists / blockers (arb) and neutral endopeptidase (nep) inhibitors
EP2222273A2 (en)	2007-11-12	2010-09-01	Novartis AG	Liquid compositions comprising valsartan
US20130137737A1 (en)	2010-08-03	2013-05-30	Novartis Ag	Highly crystalline valsartan
WO2012056294A1 (en)	2010-10-29	2012-05-03	Jubilant Life Sciences Ltd.	An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
CN102603723B (zh) *	2011-01-20	2014-10-08	江苏豪森医药集团有限公司	阿齐沙坦有机胺盐及其制备方法和用途
US8558008B2 (en)	2013-02-28	2013-10-15	Dermira, Inc.	Crystalline glycopyrrolate tosylate
EP3473615B1 (en)	2013-02-28	2022-01-19	Journey Medical Corporation	Glycopyrrolate salts
US9006462B2 (en)	2013-02-28	2015-04-14	Dermira, Inc.	Glycopyrrolate salts
WO2017012600A1 (en)	2015-07-20	2017-01-26	Zentiva, K.S.	A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
WO2017042700A1 (en) *	2015-09-07	2017-03-16	Sun Pharmaceutical Industries Limited	Solid forms of valsartan and sacubitril
CN105541741A (zh) *	2016-01-14	2016-05-04	青岛友诚高新技术有限公司	一种具有治疗冠心病活性的化合物及其制备方法
WO2018002673A1 (en)	2016-07-01	2018-01-04	N4 Pharma Uk Limited	Novel formulations of angiotensin ii receptor antagonists
CN106243056A (zh) *	2016-07-29	2016-12-21	陈欣怡	一种缬沙坦的新型固体形式
US10745363B2 (en) *	2016-09-02	2020-08-18	Nanjing Noratech Pharmaceuticals Co., Ltd	Crystal forms of valsartan disodium salt
TWI648267B (zh) *	2016-09-02	2019-01-21	諾瑞特國際藥業股份有限公司	纈沙坦二鈉鹽新晶型
RU2019115782A (ru)	2016-10-28	2020-11-30	Биокон Лимитед	Аморфный тринатрий сакубитрил вальсартан и способ его получения
WO2018178295A1 (en)	2017-03-31	2018-10-04	Alfred E. Tiefenbacher (Gmbh & Co. Kg)	Stable hot-melt extrudate containing valsartan and sacubitril
US11382866B2 (en) *	2017-07-06	2022-07-12	Mankind Pharma Ltd.	Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en)	2017-07-28	2019-01-31	Synthon B.V.	PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
EP3694493A1 (en)	2017-10-13	2020-08-19	Alfred E. Tiefenbacher (GmbH & Co. KG)	Tablet containing valsartan and sacubitril
EP3498698A1 (en)	2017-12-15	2019-06-19	Mankind Pharma Ltd	Solid forms of valsartan disodium and process of preparation thereof
CN108794418A (zh) *	2018-09-18	2018-11-13	中国药科大学	一种缬沙坦烟酰胺共无定形物
EP3766484B1 (en)	2019-07-19	2021-08-25	Zentiva, K.S.	Solid pharmaceutical dosage form comprising valsartan and sacubitril
EP4037679A4 (en) *	2019-12-02	2023-11-08	Harman Finochem Limited	PROCESS FOR PREPARING HIGHLY PURE VALSARTAN

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4499017A (en) *	1983-06-06	1985-02-12	Pfizer Inc.	Beta-lactamase inhibiting 6-(alkoxyamino-methyl) penicillanic acid 1,1-dioxide and derivatives
PH30484A (en) *	1990-02-19	1997-05-28	Ciba Geigy	Acy compounds pharmaceutical composition containing said compound and method of use thereof
JPH05105698A (ja) *	1991-06-13	1993-04-27	Takeda Chem Ind Ltd	ホスホン酸誘導体、その製造法および用途
JPH09510225A (ja)	1994-03-17	1997-10-14	チバ−ガイギーアクチェンゲゼルシャフト	バルサルタンを用いる糖尿病性ネフロパシーの治療
CA2214143A1 (en)	1995-04-07	1996-10-10	Marc De Gasparo	Combination compositions containing benazepril or benazeprilat and valsartan
ATE225657T1 (de)	1995-10-06	2002-10-15	Novartis Erfind Verwalt Gmbh	Ati-rezeptorantagonisten zur verhinderung und behandlung des postischemischen nervenversagens und zum schutze ischemischer nieren
GB9613470D0 (en)	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
GT199800126A (es)	1997-08-29	2000-01-29		Terapia de combinacion.
IT1301759B1 (it) *	1998-06-19	2000-07-07	Nicox Sa	Sali nitrati di farmaci antiipertensivi
US6383471B1 (en) *	1999-04-06	2002-05-07	Lipocine, Inc.	Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
KR100529658B1 (ko)	2000-07-19	2005-11-21	노파르티스 아게	발사르탄 염

2001
- 2001-07-17 KR KR10-2003-7000815A patent/KR100529658B1/ko not_active IP Right Cessation
- 2001-07-17 AU AU2001289672A patent/AU2001289672B2/en not_active Ceased
- 2001-07-17 CZ CZ20030117A patent/CZ303389B6/cs not_active IP Right Cessation
- 2001-07-17 DK DK01969407T patent/DK1313714T3/da active
- 2001-07-17 SI SI200130881T patent/SI1313714T1/sl unknown
- 2001-07-17 AT AT01969407T patent/ATE406355T1/de active
- 2001-07-17 ES ES01969407T patent/ES2309090T3/es not_active Expired - Lifetime
- 2001-07-17 EP EP01969407A patent/EP1313714B1/en not_active Expired - Lifetime
- 2001-07-17 US US10/333,100 patent/US20030207930A1/en not_active Abandoned
- 2001-07-17 CN CN018130399A patent/CN1216873C/zh not_active Expired - Lifetime
- 2001-07-17 AR ARP010103417A patent/AR032758A1/es not_active Application Discontinuation
- 2001-07-17 CA CA2415962A patent/CA2415962C/en not_active Expired - Fee Related
- 2001-07-17 SK SK55-2003A patent/SK287558B6/sk not_active IP Right Cessation
- 2001-07-17 BR BR0112665-2A patent/BR0112665A/pt not_active IP Right Cessation
- 2001-07-17 HU HU0300731A patent/HU229280B1/hu not_active IP Right Cessation
- 2001-07-17 DE DE60135560T patent/DE60135560D1/de not_active Expired - Lifetime
- 2001-07-17 AU AU8967201A patent/AU8967201A/xx active Pending
- 2001-07-17 PE PE2001000723A patent/PE20020613A1/es not_active Application Discontinuation
- 2001-07-17 MY MYPI20013368A patent/MY136446A/en unknown
- 2001-07-17 CN CNB2005100077076A patent/CN100413852C/zh not_active Expired - Lifetime
- 2001-07-17 PT PT01969407T patent/PT1313714E/pt unknown
- 2001-07-17 IL IL15388201A patent/IL153882A0/xx unknown
- 2001-07-17 MY MYPI20064483 patent/MY152846A/en unknown
- 2001-07-17 WO PCT/EP2001/008253 patent/WO2002006253A1/en active IP Right Grant
- 2001-07-17 JP JP2002512157A patent/JP4102664B2/ja not_active Expired - Fee Related
- 2001-07-17 MX MXPA03000525A patent/MXPA03000525A/es active IP Right Grant
- 2001-07-17 PL PL360737A patent/PL205715B1/pl not_active IP Right Cessation
- 2001-07-17 RU RU2003104789/04A patent/RU2275363C2/ru not_active IP Right Cessation
- 2001-07-17 NZ NZ52355701A patent/NZ523557A/xx not_active IP Right Cessation
2003
- 2003-01-09 IL IL153882A patent/IL153882A/en active IP Right Grant
- 2003-01-10 ZA ZA200300285A patent/ZA200300285B/en unknown
- 2003-01-17 NO NO20030232A patent/NO326504B1/no not_active IP Right Cessation
- 2003-01-17 EC EC2003004436A patent/ECSP034436A/es unknown
- 2003-11-13 HK HK03108267.6A patent/HK1055963A1/xx not_active IP Right Cessation
2007
- 2007-02-23 US US11/678,284 patent/US20070149587A1/en not_active Abandoned
2008
- 2008-08-05 US US12/186,172 patent/US8278339B2/en not_active Expired - Lifetime
- 2008-10-27 CY CY20081101215T patent/CY1108559T1/el unknown
- 2008-11-19 AR ARP080105034A patent/AR069374A2/es not_active Application Discontinuation
2012
- 2012-08-30 US US13/599,032 patent/US20120329844A1/en not_active Abandoned
2013
- 2013-11-15 US US14/081,441 patent/US9499499B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
PT1313714E (pt)	2008-11-03
WO2002006253A1 (en)	2002-01-24
IL153882A0 (en)	2003-07-31
ES2309090T3 (es)	2008-12-16
NO20030232L (no)	2003-01-17
CZ303389B6 (cs)	2012-08-29
AU2001289672B2 (en)	2005-12-08
US20070149587A1 (en)	2007-06-28
US20120329844A1 (en)	2012-12-27
CN1680341A (zh)	2005-10-12
PL205715B1 (pl)	2010-05-31
SK552003A3 (en)	2003-07-01
CZ2003117A3 (cs)	2003-05-14
SI1313714T1 (sl)	2009-02-28
MY152846A (en)	2014-11-28
CN1216873C (zh)	2005-08-31
MXPA03000525A (es)	2003-05-14
MY136446A (en)	2008-10-31
RU2275363C2 (ru)	2006-04-27
NO20030232D0 (no)	2003-01-17
US20140073677A1 (en)	2014-03-13
ZA200300285B (en)	2004-03-25
KR20030015888A (ko)	2003-02-25
NO326504B1 (no)	2008-12-15
CN1443176A (zh)	2003-09-17
HU229280B1 (en)	2013-10-28
US8278339B2 (en)	2012-10-02
AU8967201A (en)	2002-01-30
US20080293791A1 (en)	2008-11-27
CA2415962A1 (en)	2002-01-24
AR069374A2 (es)	2010-01-20
HUP0300731A3 (en)	2006-05-29
DK1313714T3 (da)	2008-12-15
ECSP034436A (es)	2003-03-10
JP4102664B2 (ja)	2008-06-18
SK287558B6 (sk)	2011-02-04
JP2004504307A (ja)	2004-02-12
US20030207930A1 (en)	2003-11-06
CA2415962C (en)	2010-07-06
HUP0300731A2 (hu)	2003-09-29
EP1313714B1 (en)	2008-08-27
PL360737A1 (en)	2004-09-20
NZ523557A (en)	2004-12-24
CY1108559T1 (el)	2014-04-09
IL153882A (en)	2009-09-01
DE60135560D1 (de)	2008-10-09
AR032758A1 (es)	2003-11-26
EP1313714A1 (en)	2003-05-28
ATE406355T1 (de)	2008-09-15
BR0112665A (pt)	2003-06-24
KR100529658B1 (ko)	2005-11-21
CN100413852C (zh)	2008-08-27
US9499499B2 (en)	2016-11-22
PE20020613A1 (es)	2002-08-07

Publication	Publication Date	Title
AU8967201A (en)	2002-01-30	Valsartan salts
EP1349851A4 (en)	2004-09-08	COMPOUNDS
AU7847201A (en)	2002-01-30	Tetrazole derivatives
GB0019950D0 (en)	2000-09-27	Compounds
AU2405002A (en)	2002-05-27	Dehalogeno compounds
AU7440101A (en)	2002-01-14	Novel tetrazole derivatives
GB0015900D0 (en)	2000-08-23	New salt form
GB0005200D0 (en)	2000-04-26	New salt form
AU146698S (en)	2002-02-04	Reel
GB0009457D0 (en)	2000-06-07	Compounds
GB0006454D0 (en)	2000-05-10	Compounds
GB0018351D0 (en)	2000-09-13	Compounds
GB0014652D0 (en)	2000-08-09	Compounds
GB0014642D0 (en)	2000-08-09	Compounds
GB0019578D0 (en)	2000-09-27	Polysulphamated compounds
GB0014641D0 (en)	2000-08-09	Compounds
GB0015853D0 (en)	2000-08-23	Compounds
GB0009456D0 (en)	2000-06-07	Compounds
GB0008727D0 (en)	2000-05-31	Compounds
GB0007404D0 (en)	2000-05-17	Compounds
GB0006800D0 (en)	2000-05-10	Compounds
GB0018306D0 (en)	2000-09-13	Compounds
GB0006797D0 (en)	2000-05-10	Compounds
GB0003633D0 (en)	2000-04-05	Compounds
GB0006457D0 (en)	2000-05-10	Compounds

Legal Events

Date	Code	Title	Description
2015-02-13	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20140717